US-based medicine company Eli Lilly to invest $3B in a new manufacturing facility in the Netherlands to expand production and ...

Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase ...

Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerabilit ...

The portfolio generated a solid absolute return in Q3, but it trailed the MSCI AC World Index. Read more here.

Eli Lilly (LLY) said on Thursday that eloralintide, its experimental amylin receptor agonist for obesity, helped patients ...

The following segment was excerpted from the Artisan Global Opportunities Fund Q3 2025 Commentary. During the quarter, we initiated new positions in Spotify, L3Harris Technologies and Insmed. Spotify ...